Regulatory Novartis receives European Commission approval for Itvisma for spinal muscular atrophy PharmaTimesEC backs first gene replacement therapy for broad sma populationRare DiseaseRead full story pharminent July 2, 2026 (Last updated: July 3, 2026) PharmaTimes EC backs first gene replacement therapy for broad sma population Rare Disease Read full story Post navigation Previous: AZ forges ever-closer ties with China’s CSPC PharmaNext: Biogen Bets on Tau at AAIC: Diranersen Phase 2 CELIA Data Related Stories Regulatory UK regulators greenlight Lilly’s Foundayo, intensifying Novo competition pharminent August 11, 2026 Regulatory Replimune rebounds to win FDA approval of melanoma drug pharminent August 6, 2026 Regulatory Takeda’s first-in-class narcolepsy drug claims FDA approval pharminent August 6, 2026
